Ocular Therapeutix (OCUL) Stock Statistics & Valuation Metrics

Ocular Therapeutix has a market cap or net worth of $1.40B. The enterprise value is $1.10B.

Ocular Therapeutix has 159,286,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ocular Therapeutix’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -41.05%.

The current PE Ratio of Ocular Therapeutix is -6.98. Ocular Therapeutix’s PEG ratio is -0.59.

In the last 12 months, Ocular Therapeutix had revenue of 63.72M and earned -193.51M in profits. Earnings per share was -1.22.

In the last 12 months, operating cash flow was -134.68M and capital expenditures -1.29M, giving a free cash flow of -135.97M billion.

Ocular Therapeutix pays an annual dividend of ―, resulting in a dividend yield of ―

Ocular Therapeutix upcoming earnings date is Mar 9, 2026, TBA Not Confirmed.

Ocular Therapeutix as a current ratio of 10.66, with Debt / Equity ratio of 24.03%

In the past 12 months, Ocular Therapeutix has paid 0.00 in taxes.

Ocular Therapeutix EV to EBITDA ratio is -5.88, with an EV/FCF ratio of -7.61.

Ocular Therapeutix has $392.10M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$316.32M billion.

Gross margin is 91.16%, with operating margin of -269.57%, and net profit margin of -303.67%.

The average price target for Ocular Therapeutix is $17.78, which is 11.43% higher than the current price. The consensus rating is Strong Buy